Clicky

Crossject(ALCJ) News

Date Title
Jun 26 Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Feb 6 Crossject provides strategic update on priorities for 2024
Jan 9 Crossject to present at Biotech Showcase on January 9 at 16:30 PT
Dec 22 Crossject signs ZEPIZURE® commercialization agreement for northern Europe
Nov 28 Crossject announces initiation of coverage by ODDO BHF
Jul 20 Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand